마이코플라스마 폐렴에서 조기 스테로이드 사용의 유용성 = Efficacy of early steroid use in Mycoplasma pneumoniae pneumonia

다국어 초록 (Multilingual Abstract)

Purpose: The aim of this study was to evaluate whether or not the early use of steroid is useful for treating Mycoplasma pneumoniae pneumonia.
Methods: A prospective study was conducted on 85 patients with M. pneumoniae pneumonia admitted to Gwangju Christian Hos-pital between September 2015 and April 2016. A total of 85 patients were enrolled. Of these, 33 were treated with steroids (methyl-prednisolone 1 mg/kg/day), while 52 were not; both were treated with macrolides. The overall duration of fever was compared be-tween the 2 groups and findings on chest radiographs were evaluated for their deterioration.
Results: The duration of fever after admission (1.36±0.92 days vs. 2.17±1.30 days, P=0.003) and the overall duration of fever (4.42±2.13 days vs. 6.07±2.59 days, P=0.003) were significantly lower in the steroid group. The duration of fever before admission was not different between the steroid and macrolide groups (3.06±1.74 days vs. 3.90±2.21 days, P=0.068). On chest radiographs taken 3 days later, 1 of 33 patients in the steroid group and 5 of 50 patients in the macrolide group worsened, although there was no statistically significant difference between the 2 groups (P=0.395). There was no significant difference in the duration of hospi-talization between the 2 groups (6.72±1.54 days vs. 6.92±1.87 days, P=0.618).
Conclusion: Early administration of steroids on patients with M. pneumoniae pneumonia reduced the duration of fever, but there was no difference in duration of admission and x-ray deterioration. (Allergy Asthma Respir Dis 2017;5:280-286)

참고문헌 (Reference)

1 Radisic M, "Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment" 31 : 1507-1511, 2000

2 Miyashita N, "Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults" 21 : 153-160, 2015

3 Lee KY, "Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children" 41 : 263-268, 2006

4 Yamada M, "Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States" 31 : 409-411, 2012

5 Okada T, "Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children" 55 : 1642-1649, 2012

6 Waites KB, "New concepts of Mycoplasma pneumoniae infections in children" 36 : 267-278, 2003

7 Kawai Y, "Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients" 57 : 4046-4049, 2013

8 Bébéar C, "Mycoplasma pneumoniae: susceptibility and resistance to antibiotics" 6 : 423-431, 2011

9 정혜원, "Mycoplasma pneumoniae 특이 항체검사에서 입자응집법과 효소면역 측정법의 비교" 대한진단검사의학회 2 (2): 41-46, 2012

10 Tamura A, "Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children" 57 : 223-228, 2008

11 Inamura N, "Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level" 20 : 270-273, 2014

12 Zheng X, "Macrolide-resistant Mycoplasma pneumoniae, United States" 21 : 1470-1472, 2015

13 Averbuch D, "Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010" 17 : 1079-1082, 2011

14 신정은, "Increased risk of refractory Mycoplasma pneumoniae pneumonia in children with atopic sensitization and asthma" 대한소아과학회 57 (57): 271-277, 2014

15 Peuchant O, "Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis" 64 : 52-58, 2009

16 Chan ED, "Fulminant Mycoplasma pneumoniae pneumonia" 162 : 133-142, 1995

17 Atkinson TP, "Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections" 32 : 956-973, 2008

18 Chen ZR, "Epidemiology of community-acquired Mycoplasma Pneumoniae respiratory tract infections among hospitalized Chinese children, including relationships with meteorological factors" 17 : 20-26, 2013

19 Chironna M, "Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children" 66 : 734-737, 2011

20 Luo Z, "Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children" 49 : 377-380, 2014

21 윤유숙, "Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study" 대한감염학회 46 (46): 239-247, 2014

22 Yoo SJ, "Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance" 56 : 6393-6396, 2012

23 Youn YS, "Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia" 10 : 48-, 2010

24 Miyashita N, "Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit" 56 (56): 1625-1629, 2007

25 Kawai Y, "Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients" 17 : 354-362, 2012

26 Wang M, "Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children" 29 : 18-23, 2014